Gastrointestinal symptoms on the rise, but still fewer than before the COVID-19 pandemic In 2022, the number of enteric infections – which mainly cause gastrointestinal symptoms – was higher than it was in the previous two years. However, the total number of infections was still lower than before the coronavirus pandemic.
Less greenhouse gas emissions across the supply chain: survey for policy development The Dutch Climate Agreement contains measures to reduce greenhouse gas emissions in the Netherlands. Many products used in the Netherlands are manufactured abroad.
Insufficient knowledge to protect the health of the Dutch population from climate change The climate is changing. This process is already affecting the health of people in the Netherlands. As such, it is important to take immediate action to prepare the Netherlands and its population for climate change and to reduce the effects on health
RIVM magazine special edition on Climate Change and Health The RIVM Magazine special edition on Climate change and Health showcases the scope of RIVM’s work on this topic.
Safety of materials and products already starts at the design phase The Ministry of Infrastructure and Water Management aims to ensure that all new materials and technological developments are safe in 2050.
Breast cancer screening resumes on Bonaire after COVID-19 hiatus Women aged 50 to 75 years on Bonaire can participate in the breast cancer screening programme again as of Wednesday, May 26, 2021. This was temporarily halted in 2020 due to the COVID-19 pandemic.
Health effects due to titanium nanoparticles in food and toothpaste cannot be excluded Health effects due to exposure to titanium dioxide nanoparticles via food, food supplements and toothpaste cannot be excluded.
Tool for risk assessment of nanomaterials in cosmetics Both regulators and manufacturers need to evaluate and manage consumer health risks that may be posed by the use of nanomaterials in cosmetics.
Nanotechnology increasingly used in medical devices The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.
Cost-effective risk assessment of nanomaterials may be feasible Companies, authorities and scientists can save time, money and test animals in the risk assessment of nanomaterials by using available data.